Emily Jeffery1, Yc Gary Lee2,3,4, Joanne McVeigh5,6, Leon Straker7, Troy Wooding2, Robert U Newton1,8, Carolyn Peddle-McIntyre9. 1. Exercise Medicine Research Institute, Edith Cowan University, Joondalup, WA, 6027, Australia. 2. Respiratory Department, Sir Charles Gairdner Hospital, Nedlands, WA, Australia. 3. Institute for Respiratory Health, Nedlands, WA, Australia. 4. School of Medicine and Pharmacology, University of Western Australia, Crawley, Australia. 5. School of Occupational Therapy and Social Work, Curtin University, Bentley, Australia. 6. Exercise Laboratory, School of Physiology, University of Witwatersrand, Johannesburg, South Africa. 7. School of Physiotherapy and Exercise Science, Curtin University, Bentley, Australia. 8. UQ Centre for Clinical Research, University of Queensland, St Lucia, Australia. 9. Exercise Medicine Research Institute, Edith Cowan University, Joondalup, WA, 6027, Australia. c.mcintyre@ecu.edu.au.
Abstract
PURPOSE: Malignant pleural effusion (MPE) affects 1 million people worldwide annually and can significantly impair physical activity. Accelerometry is a validated method of objectively assessing physical activity. The purpose of this study was to determine the compliance in patients with MPE to accelerometry and describe their activity. METHODS: Patients with MPE wore an Actigraph GT3X accelerometer over a 7-day continuous wear protocol. Compliance was measured as the percent of patients who had ≥4 valid days (i.e., 8-h/day of waking wear-time). Eastern Cooperative Oncology Group performance status was documented the day of actigraphy initialization. RESULTS: Forty-six patients with MPE received accelerometers; 44 (95.7%) returned their device. No complications were reported on their use. Forty subjects (90.9%) had ≥4 valid days of wear-time. Patients spent most of their waking hours sedentary [mean 11.0 h (SD 1.95)], with limited participation in moderate and vigorous physical activity [mean 9.5 min (SD 14.16)]. Compared to patients with better performance status (n = 32), patients with poorer performance status (n = 11) spent significantly more hours/day sedentary [mean difference 2.1 (CI 0.86-3.32); p = 0.001], as did those who survived <3 months (n = 5) compared to >12 months (n = 27) [mean difference 2.6 (CI 0.49-4.77); p = 0.013). CONCLUSION: Accelerometry was applied successfully in patients with MPE with high compliance and no adverse events. This is the first reported objectively measured physical activity in patients with MPE and revealed high sedentary behavior and low physical activity. The data reflected patient performance status and discriminated between survival groups. Accelerometry can provide a useful measure for future interventional studies in patients with MPE.
PURPOSE:Malignant pleural effusion (MPE) affects 1 million people worldwide annually and can significantly impair physical activity. Accelerometry is a validated method of objectively assessing physical activity. The purpose of this study was to determine the compliance in patients with MPE to accelerometry and describe their activity. METHODS:Patients with MPE wore an Actigraph GT3X accelerometer over a 7-day continuous wear protocol. Compliance was measured as the percent of patients who had ≥4 valid days (i.e., 8-h/day of waking wear-time). Eastern Cooperative Oncology Group performance status was documented the day of actigraphy initialization. RESULTS: Forty-six patients with MPE received accelerometers; 44 (95.7%) returned their device. No complications were reported on their use. Forty subjects (90.9%) had ≥4 valid days of wear-time. Patients spent most of their waking hours sedentary [mean 11.0 h (SD 1.95)], with limited participation in moderate and vigorous physical activity [mean 9.5 min (SD 14.16)]. Compared to patients with better performance status (n = 32), patients with poorer performance status (n = 11) spent significantly more hours/day sedentary [mean difference 2.1 (CI 0.86-3.32); p = 0.001], as did those who survived <3 months (n = 5) compared to >12 months (n = 27) [mean difference 2.6 (CI 0.49-4.77); p = 0.013). CONCLUSION: Accelerometry was applied successfully in patients with MPE with high compliance and no adverse events. This is the first reported objectively measured physical activity in patients with MPE and revealed high sedentary behavior and low physical activity. The data reflected patient performance status and discriminated between survival groups. Accelerometry can provide a useful measure for future interventional studies in patients with MPE.
Authors: Charles E Matthews; Kong Y Chen; Patty S Freedson; Maciej S Buchowski; Bettina M Beech; Russell R Pate; Richard P Troiano Journal: Am J Epidemiol Date: 2008-02-25 Impact factor: 4.897
Authors: Vinicius Cavalheri; Sue Jenkins; Nola Cecins; Martin Phillips; Lucas H Sanders; Kylie Hill Journal: Chron Respir Dis Date: 2015-12-31 Impact factor: 2.444
Authors: Andrea L Cheville; Paul J Novotny; Jeffrey A Sloan; Jeffrey R Basford; Jason A Wampfler; Yolanda I Garces; Aminah Jatoi; Ping Yang Journal: J Pain Symptom Manage Date: 2011-03-12 Impact factor: 3.612
Authors: Catrine Tudor-Locke; Tiago V Barreira; John M Schuna; Emily F Mire; Jean-Philippe Chaput; Mikael Fogelholm; Gang Hu; Rebecca Kuriyan; Anura Kurpad; Estelle V Lambert; Carol Maher; José Maia; Victor Matsudo; Tim Olds; Vincent Onywera; Olga L Sarmiento; Martyn Standage; Mark S Tremblay; Pei Zhao; Timothy S Church; Peter T Katzmarzyk Journal: Int J Behav Nutr Phys Act Date: 2015-02-11 Impact factor: 6.457
Authors: Amelia O Clive; Brennan C Kahan; Clare E Hooper; Rahul Bhatnagar; Anna J Morley; Natalie Zahan-Evans; Oliver J Bintcliffe; Rogier C Boshuizen; Edward T H Fysh; Claire L Tobin; Andrew R L Medford; John E Harvey; Michel M van den Heuvel; Y C Gary Lee; Nick A Maskell Journal: Thorax Date: 2014-08-06 Impact factor: 9.139
Authors: Deirdre B Fitzgerald; Calvin Sidhu; Charley Budgeon; Ai Ling Tan; Catherine A Read; Benjamin C H Kwan; Nicola Ann Smith; Edward T Fysh; Sanjeevan Muruganandan; Tajalli Saghaie; Ranjan Shrestha; Arash Badiei; Phan Nguyen; Andrew Burke; John Goddard; Morgan Windsor; Julie McDonald; Gavin Wright; Kasia Czarnecka; Parthipan Sivakumar; Kazuhiro Yasufuku; David J Feller-Kopman; Nick A Maskell; Kevin Murray; Y C Gary Lee Journal: Trials Date: 2022-06-27 Impact factor: 2.728
Authors: Scott A Fisher; Carolyn J Peddle-McIntyre; Kimberley Burton; Robert U Newton; Elly Marcq; Richard A Lake; Anna K Nowak Journal: BMC Res Notes Date: 2020-09-15
Authors: Milan Kos; Esther N Pijnappel; Laurien M Buffart; Britt R Balvers; Caroline S Kampshoff; Johanna W Wilmink; Hanneke W M van Laarhoven; Martijn G H van Oijen Journal: Support Care Cancer Date: 2021-06-12 Impact factor: 3.603